Evidence map›Paper›PMID 30851441›Full record

ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2019

Early-Stage NSCLC: Advances in Thoracic Oncology 2018.

Raymond U Osarogiagbon, Giulia Veronesi, Wentao Fang, Simon Ekman, Kenichi Suda, Joachim G Aerts, Jessica Donington

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Survival After Mediastinal Node Dissection, Systematic Sampling, or Neither for Early Stage NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Association ofJournal of research in health sciences · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raymond U OsarogiagbonMultidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee. Electronic address: rosarogi@bmg.md.
Giulia VeronesiDivision of Thoracic and General Surgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
Wentao FangDepartment of Thoracic Surgery, Shanghai Chest Hospital, Jiaotong University Medical School, Shanghai, China.
Simon EkmanThoracic Oncology Center, Karolinska University Hospital/Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Kenichi SudaDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Joachim G AertsThoracic Oncology Department, Erasumus University Medical Center, Rotterdam, Netherlands.
Jessica DoningtonSection of Thoracic Surgery, University of Chicago, Chicago, Illinois.

Funding

Improving pathologic nodal staging of resected lung cancerR01CA172253 · NCI · UNIVERSITY OF MEMPHIS · PI OSAROGIAGBON, RAYMOND U · 2013 to 2022
$4.8M
NCI NIH HHS R01 CA172253
6 · The paper itself

Abstract

2018 was a banner year for all thoracic oncology, but especially for early-stage NSCLC. Three seminal events occurred in the approximately 18 months from mid-2017 to the end of 2018: in June 2017 at the American Society of Clinical Oncology Annual Meeting a small, relatively unheralded study from Max Diehn's group at Stanford University reported on the use of a novel "cancer personalized profiling by deep sequencing" circulating tumor-DNA technology to identify minimal residual disease in patients after curative-intent radiation or surgery for NSCLC; in April 2018 at the American Association for Cancer Research Annual Meeting, Drew Pardoll presented a small pilot study of 21 patients who had received two doses of preoperative nivolumab; in September 2018, at the 19th World Conference on Lung Cancer, Harry J. De Koning presented the long-awaited results of the Dutch-Belgian Lung Cancer Screening Trial (NELSON). These three seminal studies, along with others which are reviewed in this paper, promise to accelerate our progress towards a world in which lung cancer is identified early, more patients undergo curative-intent treatment that achieves the promised cure, and those at risk for failure after treatment are identified early, when the cancer remains most vulnerable. The day is around the corner when lung cancer is defanged and no longer the worldwide terror it currently is. We herein present an overview of the most recent body of work that moves us inexorably towards that day.

Indexed as

Carcinoma, Non-Small-Cell LungHumansLung NeoplasmsNeoplasm StagingSurvival AnalysisAdjuvant therapyimmunotherapyneoadjuvant therapynon-surgical treatmentscreeningsurgical resection

Identifiers

PMID30851441
PMCPMC6534444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.